Sellas Life Sciences Group, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
SELLAS Life Sciences Group reports increased cash reserves and positive clinical trial developments for its cancer therapeutics, alongside continued operational losses.
NASDAQ
SELLAS Life Sciences Group reports a net loss of $8.4 million for Q1 2026, with increased R&D spending and a robust cash balance of $107.1 million.
NASDAQ
SELLAS Life Sciences Group, Inc. reported a reduced net loss and significantly increased cash reserves, driven by successful capital raises and positive clinical trial advancements for its SLS009 candidate.
NASDAQ
SELLAS Life Sciences Group reports reduced net loss and operating expenses in Q2 2025, driven by progress in its oncology pipeline and recent financing activities, but faces ongoing liquidity challenges.
NASDAQ
10-Q: SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
SELLAS Life Sciences Group reports its financial results for the first quarter of 2025, highlighting progress in its clinical trials and recent financial activities.
NASDAQ
SELLAS Life Sciences reported a net loss of $24.1 million for the nine months ended September 30, 2024, while providing updates on its clinical programs for GPS and SLS009.
NASDAQ
SELLAS Life Sciences Group reported its financial results for the second quarter of 2024, highlighting clinical trial progress and recent capital raising activities.
NASDAQ
SELLAS Life Sciences reported a net loss of $9.6 million for the first quarter of 2024, while also highlighting clinical trial advancements and recent capital raises.